American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of patients with richter transformation without prior chemoimmunotherapy for CLL/SLL: An international multicenter retrospective study
    Meeting Abstract

    Kittai, A. S.; Huang, Y.; Miller, S.; Allan, J. N.; Bhat, S. A.; Bond, D. A.; Brander, D. M.; Byrd, J. C.; Chavez, J. C.; Chong, E. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed / refractory marginal zone lymphoma: Results from phase 1/2 BRUIN study
    Meeting Abstract

    Patel, K.; Vose, J. M.; Nasta, S. D.; Brown, J. R.; Maddocks, K. J.; Woyach, J. A.; Shah, N. N.; Fakhri, B.; Tessoulin, B.; Ma, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Obecabtagene autoleucel (obe-cel, AUTO1) for relapsed/refractory adult B-cell acute lymphoblastic leukemia (R/R B-ALL): Pooled analysis of the ongoing FELIX phase Ib/II study
    Meeting Abstract

    Roddie, C.; Sandhu, K. S.; Tholouli, E.; Shaughnessy, P.; Barba, P.; Guerreiro, M.; Bishop, M. R.; Yared, J. A.; Ghobadi, A.; Yallop, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Invasive fungal infections after CAR T-cell therapy for B-cell lymphoma: A study from the French DESCART registry
    Meeting Abstract

    Bouvier, A.; Durand, A.; Gower, N.; Castilla-Llorente, C.; Campidelli, A.; Dulery, R.; Gangneux, J. P.; Joris, M.; Eloit, M.; Fayard, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pelabresib in combination with ruxolitinib for Janus Kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study
    Meeting Abstract

    Rampal, R. K.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma
    Meeting Abstract

    Morschhauser, F.; Dahiya, S.; Palomba, M. L.; Garcia-Sancho, A. M.; Reguera, J. L.; Kuruvilla, J.; Jaeger, U.; Cartron, G.; Izutsu, K.; Dreyling, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The composite health risk assessment model (CHARM) to predict 1-year non-relapse mortality (NRM) among older recipients of allogeneic transplantation: A prospective BMT-CTN study 1704
    Meeting Abstract

    Artz, A.; Logan, B. R.; Saber, W.; Geller, N.; Bellach, A.; Kou, J.; Wood, W.; McCarty, J. M.; Knight, T. G.; Runaas, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3
    Meeting Abstract

    Otero, P. R.; Ailawadhi, S.; Arnulf, B.; Patel, K. K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N. S.; Costa, L.; Vij, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Improved overall survival with axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma among the elderly: A subgroup analysis of ZUMA-7
    Meeting Abstract

    Kersten, M. J.; Farooq, U.; Rapoport, A. P.; Locke, F. L.; Leslie, L. A.; Ghobadi, A.; Miklos, D. B.; Jacobson, C. A.; Munoz, J. L.; Johnston, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Treatment patterns and outcomes for patients with classic Hodgkin lymphoma (cHL) and cardiomyopathy with low ejection fraction (EF): Real-world evidence (RWE) from 16 US academic centers
    Meeting Abstract

    Annunzio, K.; McLaughlin, E.; Voorhees, T.; Shea, L. K.; Sumransub, N.; Rose, A.; Olszewski, A. J.; Bailey, N.; Patel, K.; Moyo, T. K.; more...
    Blood (2023)

    Fulltext@MSK | Save